Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and DLI for Relapsed AML Post-Transplant
NCT03537599Phase 2Terminated
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in acute myeloid leukemia (AML). Primary endpoint: Safety and Feasibility Defined as the Establishment of the Appropriate Dose Level of Donor Lymphocyte Infusion When Given With a Fixed Dose of Daratumumab up to 6 months. Started Jan 2020; status: terminated.
02
Drugs
daratumumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03537599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537599.